Last reviewed · How we verify

minoxidil + finasteride — Competitive Intelligence Brief

minoxidil + finasteride (minoxidil + finasteride) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination antialopecia agent. Area: Dermatology.

marketed Combination antialopecia agent Potassium channels (minoxidil); 5-alpha reductase type II (finasteride) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

minoxidil + finasteride (minoxidil + finasteride) — Beijing Dayspring Pharmaceutical Technology Co., Ltd. Minoxidil stimulates hair growth by prolonging the anagen phase and improving blood flow to hair follicles, while finasteride inhibits 5-alpha reductase to reduce DHT-mediated hair loss.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
minoxidil + finasteride TARGET minoxidil + finasteride Beijing Dayspring Pharmaceutical Technology Co., Ltd marketed Combination antialopecia agent Potassium channels (minoxidil); 5-alpha reductase type II (finasteride)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination antialopecia agent class)

  1. Beijing Dayspring Pharmaceutical Technology Co., Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). minoxidil + finasteride — Competitive Intelligence Brief. https://druglandscape.com/ci/minoxidil-finasteride. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: